Program
epaminurad
Also written as “Epaminurad 9 mg”, “Epaminurad 9 mg (JW Pharmaceutical)” and “Epaminurad 9 mg (Shanghai STA Pharmaceutical)”.
Its studies are mostly in Gout, led by JW Pharmaceutical.
Furthest: phase 3, since Feb 27, 20235 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| JW Pharmaceutical | 50 open or running | phase 3since Feb 27, 2023 | Feb 27, 2023 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 27, 2023First study: phase 3 study in GoutFirst studyNCT05815901 · 612 enrolled · South Korea
- May 24, 2024Phase 1 study in HealthyNCT06435442 · 57 enrolled · South Korea
- Oct 28, 2024Phase 1 study in Healthy VolunteersNCT06665425 · 18 enrolled · South Korea
- Jun 16, 2025Phase 1 study in Healthy Male AdultsNCT07036458 · 8 enrolled · United Kingdom
- Jan 1, 2026Phase 1 study in HealthyNCT07374406 · 34 enrolled · South Korea
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07374406Healthy · South Korea | 1 | Completed | Feb 19, 2026 | 34 |
| NCT07036458Healthy Male Adults · United Kingdom | 1 | Completed | Sep 5, 2025 | 8 |
| NCT06665425Healthy Volunteers · South Korea | 1 | Completed | May 2, 2025 | 18 |
| NCT06435442Healthy · South Korea | 1 | Completed | Dec 30, 2025 | 57 |
| NCT05815901Gout · South Korea | 3 | Completed | Mar 26, 2024 | 612 |
How it is read
Names in the registry
- “Epaminurad 9 mg”, 2 entries
- “Epaminurad 9 mg (JW Pharmaceutical)”, 1 entry
- “Epaminurad 9 mg (Shanghai STA Pharmaceutical)”, 1 entry
- “Epaminurad 6 mg”, 1 entry
- “14C Epaminurad Oral Solution”, 1 entry
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.